Effects of Neuromuscular Electrical Stimulation on Exercise Capacity in Respiratory Critically Ill Patients

November 5, 2023 updated by: Joan-Daniel Martí Romeu, Hospital Clinic of Barcelona
Neuromuscular electrical stimulation (NMES) implemented during the intensive care unit(ICU) stay may improve exercise capacity and prevent muscular weakness in critically ill patients with respiratory disease. Main objective: To evaluate, in respiratory critically ill patients, the effects of a conventional physiotherapy program with or without additional NMES applied only during the ICU stay on exercise capacity. Design: Randomized, controlled, double-blind clinical trial on patients (>18yo) with diagnosis on admission of acute or acute on chronic respiratory disease, on mechanical ventilation (MV) > 72h and expected MV > 24h. Intervention: Conventional physiotherapy with or without 30-minutes (5days/week) on quadriceps femoris and gluteus maximus. Patients in the control group will follow the same protocol but the device will not be activated. Measures: Demographic data, body composition through bioelectrical impedance analysis (BIA), and functional capacity before admission through Barthel scale will be registered upon inclusion. Exercise capacity through test sit-to stand, muscular strength through Medical Research Council (MRC) score and dynamometry, body composition through BIA, and functional capacity through Barthel scale will be obtained at ICU and hospital discharge.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Barcelona, Spain, 08036
        • Recruiting
        • Unidad de Vigilancia Intensiva Respiratoria (UVIR)
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis at admission: acute or acute on chronic respiratory disease
  • Mechanical ventilation > 72h at inclusion
  • Expected mechanical ventilation > 24h
  • Informed consent

Exclusion Criteria:

  • Patients re-admitted to ICU (no hospital discharge)
  • Exitus or transfer to another service/hospital
  • Respiratory instability [Inspired fraction of oxygen (FIO2) >60% or positive end-expiratory pressure (PEEP) >10 cmH2O] and/or hemodynamic instability [Mean arterial pressure ( MAP)<60mmHg although vasoactive drugs] during > 24h.
  • Pregnancy
  • Neuromuscular disease before admission
  • Skin lesions
  • Limitation of therapeutic effort
  • Mental and/or physical limitation to understand/realize tests for evaluation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Control
Conventional physiotherapy with NMEs device not activated
Conventional physiotherapy with NMES device NOT activated
Experimental: Intervention
Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise capacity
Time Frame: <48h from ICU discharge
Test sit-to-stand
<48h from ICU discharge
Exercise capacity
Time Frame: 24h before hospital discharge
Test sit-to-stand
24h before hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle strength
Time Frame: 1st day in which collaboration of the patient is ensured (through standardized 5 questions)
MRC score
1st day in which collaboration of the patient is ensured (through standardized 5 questions)
Muscle strength
Time Frame: <48 from ICU discharge
MRC score
<48 from ICU discharge
Muscle strength
Time Frame: 24h before hospital discharge
MRC score
24h before hospital discharge
Muscle strength
Time Frame: 1st day in which collaboration of the patient is ensured (through standardized 5 questions)
Dynamometry
1st day in which collaboration of the patient is ensured (through standardized 5 questions)
Muscle strength
Time Frame: <48 from ICU discharge
MRC score and dynamometry
<48 from ICU discharge
Muscle strength
Time Frame: 24h before hospital discharge
MRC score and dynamometry
24h before hospital discharge
Body composition (fat free mass)
Time Frame: <48h from inclusion
Bioelectrical impedance
<48h from inclusion
Body composition (fat free mass)
Time Frame: <48 from ICU discharge
Bioelectrical impedance
<48 from ICU discharge
Body composition (fat free mass)
Time Frame: 24h before hospital discharge
Bioelectrical impedance
24h before hospital discharge
Functional Capacity
Time Frame: <24h from inclusion
Barthel scale
<24h from inclusion
Functional Capacity
Time Frame: 24h before hospital discharge
Barthel scale
24h before hospital discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joan-Daniel Martí, Pt,PhD, Physiotherapist

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2017

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

February 28, 2017

First Submitted That Met QC Criteria

March 13, 2017

First Posted (Actual)

March 20, 2017

Study Record Updates

Last Update Posted (Actual)

November 7, 2023

Last Update Submitted That Met QC Criteria

November 5, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness Myopathy

Clinical Trials on Sham

Subscribe